Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

In vitro dynamics: imipenem/relebactam vs ceftolozano/tazobactam

ABSTRACT: High genetic barrier of imipenem/relebactam for in vitro resistance development in Pseudomonas aeruginosa XDR high-risk clones.

PROVIDER: PRJEB48951 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR7424740_1.fastq.gz	Fastqsanger.gz
	ERR7424740_2.fastq.gz	Fastqsanger.gz
	ERR7424920_1.fastq.gz	Fastqsanger.gz
	ERR7424920_2.fastq.gz	Fastqsanger.gz
	ERR7425160_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 94

Similar Datasets

The impact of heat stress on imipenem susceptibility in imipenem resistant NTHi

Project description:The purpose of the present study was to investigate the impact of heat stress for increasing imipenem susceptibility in imipenem resistant nontypeable Haemophilus influenzae (NTHi).

2019-01-15 | E-MTAB-6237 | biostudies-arrayexpress

Pseudomonas aeruginosa

Project description:Imipenem and Imipenem/Relebactam susceptibility in Pseudomonas aeruginosa.

| PRJNA873916 | ENA

The impact of heat stress on imipenem susceptibility in imipenem resistant NTHi

Project description:The impact of heat stress on imipenem susceptibility in imipenem resistant NTHi

| PRJEB23607 | ENA

Proteomics analysis of the Enterobacter cloacae response to imipenem

Project description:Recently, we have reported on a highly drug-resistant carbapenemase-producing isolate of Enterobacter cloacae (Nepal et al., Virulence. 2018; 9: 1377-1389). In the present study, we asked the question whether and, if so, how this isolate responds to a sub-inhibitory challenge with the antibiotic imipenem. To answer this question, we applied a SILAC proteomics approach that allowed the quantification of changes in the relative abundance of bacterial protein in response to imipenem. The results show that the investigated E. cloacae isolate mounts a highly specific response to counteract the detrimental effects of imipenem.

2021-08-10 | PXD013412 | Pride

Differential expression of E. coli(pBIC-1a) under imipenem exposure

Project description:pBIC-1a is a IncFIIk-IncFI blaKPC-2-producing plasmid. Transcriptomic analysis was performed to dive deeper into the biology of this prototypical successful plasmid. The transcriptional landscape of pBIC-1a was assessed without antibiotic, and differential analysis after imipenem exposure was performed on E. coli TOP10(pBIC-1a) whole transcriptome.

2018-09-15 | E-MTAB-7190 | biostudies-arrayexpress

Project description:Imipenem/relebactam Challenge Set Genome sequencing and assembly

| PRJNA523732 | ENA

Project description:Imipenem-relebactam resistance in KPC-producing Klebsiella pneumoniae

| PRJNA869900 | ENA

Project description:Resistance to imipenem-relebactam in KPC-producing Klebsiella pneumoniae

| PRJNA809903 | ENA

Project description:Induced resistance to imipenem-relebactam in KPC-producing Klebsiella pneumoniae

| PRJNA762266 | ENA

In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.

Project description:Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a novel ?-lactam-?-lactamase inhibitor combination, imipenem-relebactam, along with ceftolozane-tazobactam, imipenem, ertapenem, meropenem, ceftriaxone, and cefepime, against 282 drug-resistant isolates of Gram-negative bacilli. For isolates harboring blaKPC (n = 110), the addition of relebactam to imipenem lowered the MIC50/MIC90 from 16/>128 ?g/ml for imipenem alone to 0.25/1 ?g/ml. For isolates harboring blaCTX-M (n = 48), the MIC50/MIC90 of ceftolozane-tazobactam were 0.5/16 ?g/ml (83% susceptible). For isolates harboring blaCMY-2 (n = 17), the MIC50/MIC90 of ceftolozane-tazobactam were 4/8 ?g/ml (47% susceptible). Imipenem-relebactam was active against most KPC-producing (but not NDM- or IMP-producing) Enterobacteriaceae and is an encouraging addition to the present antibiotic repertoire.

| S-EPMC6105828 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data